Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Biomarkers To Predict Outcome after Allogeneic Hematopoietic Cell Transplant (HCT).

Shira N. Dinner, MD, Andrew Artz, MD, MS, Masha Kocherginsky, PhD, Jodie Ulaszek, MS, Daniel Pollyea, MD, Lucy Godley, MD, PhD, Richard A. Larson, MD, Olatoysi Odenike, MD, Elizabeth Rich, MD, PhD, Wendy Stock, MD, Koen van Besien, MD, Amittha Wickrema, PhD

Blood (2007) 110 (11): 1100.

https://doi.org/10.1182/blood.V110.11.1100.1100

Published: 2007

Journal Articles

Prospective Measurement of BK Virus Blood and Urine Levels, and Associations with Morbidity, in Recipients of Allogeneic Hematopoetic Stem Cell Transplants.

Peter H. O’Donnell, MD, Kate Swanson, Michelle A. Josephson, MD, Andrew S. Artz, MD, Elizabeth Rich, MD, PhD, Wendy Stock, MD, Koen van Besien, MD

Blood (2007) 110 (11): 1973.

https://doi.org/10.1182/blood.V110.11.1973.1973

Published: 2007

Journal Articles

New Cytogenetic Abnormalities Are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation (HCT).

Daniel A. Pollyea, MD, Andrew S. Artz, MD, Wendy Stock, MD, Christopher Daugherty, MD, Lucy Godley, MD PhD, Olatoyosi M. Odenike, MD, Elizabeth Rich, MD PhD, Sonali M. Smith, MD, Todd Zimmerman, MD, Yanming Zhang, PhD, Dezheng Huo, PhD, Richard Larson, MD, Koen Van Besien, MD

Blood (2006) 108 (11): 3675.

https://doi.org/10.1182/blood.V108.11.3675.3675

Published: 2006

Journal Articles

Leukemic Relapse after Allogeneic Stem Cell Transplantation with a T-Cell Depleted Reduced Intensity Conditioning (RIST) Regimen.

Daniel A. Pollyea, MD, Andrew S. Artz, MD, Wendy Stock, MD, Lucy Godley, MD, PhD, Olatoyosi M. Odenike, MD, Elizabeth Rich, MD, PhD, Sonali M. Smith, MD, Richard Larson, MD, Koen Van Besien, MD

Blood (2005) 106 (11): 2022.

https://doi.org/10.1182/blood.V106.11.2022.2022

Published: 2005

Journal Articles

Alemtuzumab (Campath 1-H) Exposure Correlates with Risk of Chronic Graft vs Host Disease and CMV Viremia after Allogeneic Transplantation.

Justin P. Kline, MD, Rajiv Swamy, MD, Dezheng Huo, Laura Michaelis, MD, Richard A. Larson, MD, Elizabeth Rich, MD, PhD, Wendy Stock, MD, Jody Ulaszek, MS, Amittha Wickrema, PhD, Andrew Artz, MD, Maher Albitar, MD, Koen van Besien, MD

Blood (2005) 106 (11): 1818.

https://doi.org/10.1182/blood.V106.11.1818.1818

Published: 2005

Journal Articles

Clinical Predictors of Transplant Related Mortality after Reduced Intensity Allogeneic Stem Cell Transplantation (RIST).

Daniel A. Pollyea, MD, Andrew S. Artz, MD, MS, Wendy Stock, MD, Sonali M. Smith, MD, Christopher Daugherty, MD, Lucy Godley, MD, PhD, Todd Zimmerman, MD, Olatoyosi M. Odenike, MD, Michael Thirman, MD, Elizabeth Rich, MD, PhD, Richard Larson, MD, Koen Van Besien, MD

Blood (2004) 104 (11): 1145.

https://doi.org/10.1182/blood.V104.11.1145.1145

Published: 2004

NARROW

Biomarkers To Predict Outcome after Allogeneic Hematopoietic Cell Transplant (HCT).

Prospective Measurement of BK Virus Blood and Urine Levels, and Associations with Morbidity, in Recipients of Allogeneic Hematopoetic Stem Cell Transplants.

New Cytogenetic Abnormalities Are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation (HCT).

Leukemic Relapse after Allogeneic Stem Cell Transplantation with a T-Cell Depleted Reduced Intensity Conditioning (RIST) Regimen.

Alemtuzumab (Campath 1-H) Exposure Correlates with Risk of Chronic Graft vs Host Disease and CMV Viremia after Allogeneic Transplantation.

Clinical Predictors of Transplant Related Mortality after Reduced Intensity Allogeneic Stem Cell Transplantation (RIST).

Email alerts

ASH Publications

American Society of Hematology

Biomarkers To Predict Outcome after Allogeneic Hematopoietic Cell Transplant (HCT).

Prospective Measurement of BK Virus Blood and Urine Levels, and Associations with Morbidity, in Recipients of Allogeneic Hematopoetic Stem Cell Transplants.

New Cytogenetic Abnormalities Are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation (HCT).

Leukemic Relapse after Allogeneic Stem Cell Transplantation with a T-Cell Depleted Reduced Intensity Conditioning (RIST) Regimen.

Alemtuzumab (Campath 1-H) Exposure Correlates with Risk of Chronic Graft vs Host Disease and CMV Viremia after Allogeneic Transplantation.

Clinical Predictors of Transplant Related Mortality after Reduced Intensity Allogeneic Stem Cell Transplantation (RIST).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only